Abiopharma

News list

Director Nader Francois 🟢 acquired 10.6K shares (2 derivative) of Moderna, Inc. (MRNA) at $48.79 Transaction Date: May 06, 2026 | Filing ID: 000088

Full text

News bot May 8, 2026, 9 p.m.
🔍 Nader Francois (Director)

Company: Moderna, Inc. (MRNA)

Report Date: 2026-05-06
Transaction Summary:
- Total transactions: 2
- Derivative instruments: 2
- Holdings reported: 0
- Total shares acquired: 10,639
Detailed Transactions and Holdings:
- Acquired 6,454 shares of Stock Option (Right to Buy) at $48.79 per share (Derivative)
  Date: 2026-05-06 | Code: A | Expires: 2036-05-06 | equity_swap_involved: 0 | shares_owned_after: 6,454.00 | transaction_form_type: 4 | Footnotes: F1
- Acquired 4,185 shares of Restricted Stock Units (Derivative)
  Date: 2026-05-06 | Code: A | equity_swap_involved: 0 | shares_owned_after: 4,185.00 | transaction_form_type: 4 | Footnotes: F2, F3, F3
Footnotes:
- F1: This option will become fully vested and exercisable on the earlier of May 6, 2027, or Moderna's next Annual Meeting of Shareholders, subject to the recipient's continued service.
- F2: Restricted stock units convert into common stock on a one-for-one basis.
- F3: The shares subject to this restricted stock unit award will vest in full on the earlier of May 6, 2027, or Moderna's next Annual Meeting of Shareholders, subject to the recipient's continued service.